

TORRENT PHARMACEUTICALS LIMITED

PART I	[Rs. in Crores except per share data]			
Statement of Standalone Audited Results for the Quarter Ended 30-Jun-2013				
Particulars	Quarter ended			Year ended
	30-Jun-2013	31-Mar-2013	30-Jun-2012	31-Mar-2013
Income from operations				
Net sales (Net of excise duty) (see note 2)	818	703	620	2618
Other operating income	67	67	29	149
Net income from operations	885	770	649	2767
Expenses				
Cost of materials consumed	212	224	176	797
Purchases of stock-in-trade	20	23	120	293
Changes in inventories of finished goods, work-in-progress and stock-in-trade	39	(24)	(49)	(110)
Employee benefits expense	104	98	88	366
Depreciation and amortisation expense	19	20	16	72
Other expenses	223	200	171	742
Total expenses	617	541	522	2160
Profit from operations before other income, finance costs and exceptional items	268	229	127	607
Other income	14	15	58	132
Profit from ordinary activities before finance costs and exceptional items	282	244	185	739
Finance costs	8	10	10	37
Profit from ordinary activities after finance costs but before exceptional items	274	234	175	702
Exceptional items	-	37	-	37
Profit from ordinary activities before tax	274	197	175	665
Tax expense	60	44	27	119
Net profit for the period	214	153	148	546
Paid-up equity share capital (Face value of Rs.5 each)	42	42	42	42
Reserves excluding revaluation reserves	-	-	-	1609
Earnings per share (of Rs. 5/- each) (not annualised):				
Basic	25.28	18.08	17.44	64.58
Diluted	25.28	18.08	17.44	64.58

PART II				
Select Information for the Quarter Ended 30-Jun-2013				
PARTICULARS OF SHAREHOLDING	Quarter ended			Year ended
	30-Jun-2013	31-Mar-2013	30-Jun-2012	31-Mar-2013
Public shareholding				
- Number of shares	24108000	24108000	24109500	24108000
- Percentage of shareholding	28.49%	28.49%	28.49%	28.49%
Promoters and Promoter group Shareholding				
(a) Pledged/Encumbered				
- Number of shares	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil
(b) Non-encumbered				
- Number of shares	60503360	60503360	60501860	60503360
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	71.51%	71.51%	71.51%	71.51%
INVESTOR COMPLAINTS	Quarter ended			
	30-Jun-2013			
Pending at the beginning of the quarter	Nil			
Received during the quarter	1			
Disposed of during the quarter	1			
Remaining unresolved at the end of the quarter	Nil			

Notes:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 26-Jul-2013. There is no qualification in the Auditors Report on this statement of financial results.
- 2 The Company operates a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

Particulars	Quarter ended			Year ended
	30-Jun-2013	30-Jun-2012	Growth %	31-Mar-2013
(A) Sales in India				
Branded sales	316	280	13%	1035
Contract manufacture	60	48	25%	231
Others	3	3	-	12
Total sales in India	379	331	15%	1278
(B) Sales outside India	441	291	52%	1347
Total sales (A+B)	820	622	32%	2625
Less:Excise duty	2	2	-	7
Net sales	818	620	32%	2618

[Rs. in Crores]

- 3 Other operating income during the current quarter, includes an amount of Rs. 42 crores (preceding quarter ended on 31-Mar-2013 Rs. 29 crores and comparative quarter ended on 30-Jun-2012 Rs. Nil) being the milestone payment arising from settlement and license agreement involving assignment of a patent.
- 4 The figures for the comparative periods have been regrouped, wherever necessary, to make them comparable with the figures for the current periods.
- 5 The Company has also prepared and published unaudited consolidated financial results for the quarter ended 30-Jun-2013, which were subjected to limited review by statutory auditors of the Company.

For TORRENT PHARMACEUTICALS LIMITED

**Place : Ahmedabad, Gujarat
Date : 26-Jul-2013**

**sd/-
SAMIR MEHTA
Executive Vice Chairman**

.... Visit us at www.torrentpharma.com....